CHICAGO — The number of injections required for the successful treatment of neovascular age-related macular degeneration could be reduced considerably with experimental therapies, new research shows.

An injection that helps to block the growth of abnormal blood vessels in the back of the eye in patients with wet age-related macular degeneration (AMD) is set to become available on the NHS in ...

Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be associated ...

A new study published in the Journal of the American Medical Association found that administration of anti–vascular ...

Background The standard of care for neovascular age-related macular degeneration (nAMD) is repeated intravitreal injection ...

According to MingMed Biotechnology, 1 the QA102-CS201 trial enrolled 150 patients with intermediate atrophic AMD and randomly ...

Reducing the number of intravitreal injections to treat age-related macular degeneration (AMD) is a top priority in current treatment research, says Paul Hahn, MD, PhD. The future of treating ...

Please provide your email address to receive an email when new articles are posted on . The approval was supported by 1-year results from the phase 3 Pagoda study. Susvimo is also approved for wet age ...

If your vision is blurry or fuzzy, or if you notice that straight lines appear curved or wavy, you may have age-related macular degeneration (AMD). This eye disease is more common in older adults and ...